🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/12/2020 30,68 31,02 28,38 28,53 -6,70% 8,60% 406.200
24/12/2020 31,68 32,00 30,29 30,58 -2,39% 5,40% 155.300
23/12/2020 32,34 32,34 30,95 31,33 -3,18% 4,30% 293.700
22/12/2020 32,04 33,10 31,83 32,36 +1,95% 3,96% 297.000
21/12/2020 31,11 32,17 30,77 31,74 -1,34% 4,50% 542.300
18/12/2020 31,94 32,85 31,06 32,17 +1,26% 5,60% 1.727.500
17/12/2020 30,99 31,88 30,32 31,77 +2,78% 5,03% 339.000
16/12/2020 31,38 31,59 29,97 30,91 -1,47% 5,16% 369.900
15/12/2020 32,47 32,58 30,79 31,37 -2,30% 5,51% 435.500
14/12/2020 30,57 32,37 30,18 32,11 +4,19% 7,16% 541.300
11/12/2020 29,27 31,46 29,14 30,82 +4,26% 7,93% 406.000
10/12/2020 29,36 30,30 28,93 29,56 +0,68% 4,65% 302.500
09/12/2020 30,25 30,97 28,60 29,36 -1,90% 7,83% 528.300
08/12/2020 27,00 29,97 27,00 29,93 +10,69% 11,00% 557.000
07/12/2020 29,05 29,81 26,79 27,04 -6,92% 10,40% 448.000
04/12/2020 28,01 29,11 27,92 29,05 +3,68% 4,25% 366.500
03/12/2020 27,23 28,24 27,11 28,02 +3,13% 4,15% 340.900
02/12/2020 26,65 27,26 26,38 27,17 +0,70% 3,30% 382.700
01/12/2020 27,64 27,86 26,89 26,98 -0,92% 3,51% 433.400
30/11/2020 25,68 27,36 25,48 27,23 +5,91% 7,32% 543.900
27/11/2020 24,39 25,91 24,39 25,71 +5,50% 6,21% 233.600
25/11/2020 25,37 25,82 24,26 24,37 -3,94% 6,13% 265.700
24/11/2020 26,38 26,57 25,33 25,37 -1,51% 4,70% 399.000
23/11/2020 24,74 25,97 24,16 25,76 +5,66% 7,32% 461.400
20/11/2020 24,08 24,74 23,55 24,38 +0,33% 4,94% 329.000
19/11/2020 23,29 24,37 23,19 24,30 +4,38% 5,05% 275.800
18/11/2020 23,40 24,20 23,00 23,28 -0,13% 5,13% 337.300
17/11/2020 22,50 23,60 22,28 23,31 +2,78% 5,88% 346.900
16/11/2020 23,01 23,63 21,70 22,68 +0,35% 8,39% 379.900
13/11/2020 23,07 23,26 22,19 22,60 +0,00% 4,64% 266.800